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The GABAA receptor complex was solubilixed from rat brain membranes in Triton X-100, enriched by 1012-S affinity 
chromatography, and subjected to DEAE anion-exchange chromatography. Two forms were distinguished by their diffe- 
rential elution during this HPLC with a KC1 gradient. They displayed similar PH]muscimol- and PH]flunitrazepam-bind- 
ing characteristics, as well as PHlflunitraxepam-binding inhibition by CL 218872. Rechromatography of these distinct 
ionic forms indicated that they were not in dynamic equilibrium during chromatography. Resolution of these two phar- 
macologically similar populations of GABA,+, receptor by anion-exchange HPLC suggests that they differ in charge 
densities, a condition which may reflect differing glycosylation or phosporylation states of the complex. 
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1. INTRODUCTION 
y-Aminobutyric acid (GABA) is recognized as a 
major inhibitory neurotransmitter in the central 
nervous system [l]. GABA may affect neuronal 
membrane potentials by acting directly upon the 
GABAA receptor and its associated Cl- channel 
complex. The gating of the Cl- channel in the 
GABA* receptor is also influenced by ben- 
zodiazepine and barbiturate binding to specific 
receptor sites on the complex [2,3]. Additional 
GABA receptors not linked to benzodiazepine- 
binding sites are also prevalent in the nervous 
system, some of which constitute a separate class 
known as GABAB receptors [4]. Considerable pro- 
gress has been made in the characterization of 
GABAA receptors purified from different species 
and regions of the nervous system (reviews [5,6]). 
Consistent with data from other neurotransmit- 
ter receptor systems, there appears to be 
heterogeneity among the GABA* receptors. Early 
evidence for GABAA receptor heterogeneity was 
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obtained in pharmacological studies of the 
associated benzodiazepine-binding site. Thus, the 
triazolopyridazine, CL 218872, and ,&carbolines 
have relatively high affinity for the type I 
benzodiazepine-binding site of GABAA receptors, 
while these ligands interact less effectively with this 
site on the type II receptor [7,8]. The two 
subclasses of benzodiazepine-binding sites which 
are coupled to GABA. receptors have differential 
ontogenies and distributions in the adult nervous 
system [8-111 as well as differential sensitivity to 
thermal inactivation in the presence of certain ions 
or GABA [ 121. The type I receptor is less easily ex- 
tracted from membranes with detergent and is 
reported to have characteristics which correlate 
with a postsynaptic element, while type II may be 
more concentrated on presynaptic endings [ 13,141. 
Partially homologous cDNA molecules corre- 
sponding to the 50 kDa a- and 55 kDa p-subunits 
of the GABAA receptor have been isolated from 
bovine brain [ 151. Photolabeling studies using 
[3H]flunitrazepam have suggested that a 59 kDa 
subunit polypeptide may be associated with the CL 
218872_insensitive, type II receptor in some tissues 
[ 161. We have identified a similar a-like GABAA 
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subunit in type II-enriched receptor preparations 
purified from neonatal cortex and spinal cord [ 171. 
Recently, Levitan et al. [18] have reported three 
distinct a-like subunit cDNAs in bovine brain 
which code for subunits they have designated al, 
(~2 and CY~. The distribution of transcripts for the 
three a-subunits displays regional differences in 
the nervous system [ 181. 
Beyond subunit composition, receptor het- 
erogeneity may be derived from the degree and 
quality of glycosylation [ 19-211 and/or 
phosphorylation [22]. Receptor subtypes which 
differ in these respects may be distinguishable by 
the density of ionized groups within the receptor 
complex. There have been no reports of non- 
denatured GABAA receptor subtypes which vary in 
terms of their ionic constitution, although 
[3H]flunitrazepam-photolabeled polypeptides are 
reported to migrate to three different positions 
during isoelectric focusing of receptor solubilized 
in urea [23]. 
Here, we have examined GABAA receptor, 
solubilized and partially purified from rat brain 
membranes, for evidence of ionic heterogeneity as 
inferred from mobility during DEAE anion- 
exchange HPLC. 
2. EXPERIMENTAL 
2.1. Receptor preparation 
For each experiment, 70 freshly dissected rat brains were 
homogenized in a Waring blender in 1 1 ice-cold Hz0 contain- 
ing 0.32 M sucrose, 0.1 mM phenylmethylsulfonyl f uoride, 
1 mM NazEDTA, 0.5 mM dithiothreitol and 40 mg/l of 
ovoinhibitor brought to pH 7.4 with Tris. The tissue was fur- 
ther homogenized using a glass Potter-Elvehjem homogenizer 
and sedimented at 1000 x g for 25 min. The supernatant fluid 
was sedimented at 25000 x g for 25 min and the pellets, 
designated Pl, resuspended in 500 ml of the homogenizing buf- 
fer without sucrose and phenylmethylsulfonyl f uoride. The 
suspension was sedimented at 8000 x g for 20 min and the 
supernatant with soft upper pellets collected and sedimented at 
48000 x g for 20 min. The pellets were resuspended in the same 
medium using a Polytron, resedimented at 48000 x g, and 
resuspended in 20 mM Tris-citrate @H 7.4) with 1 mM 
NazEDTA and 0.5 mM dithiothreitol. The membranes were 
sedimented again at 48000 x g. The pellets, designated P2, were 
resuspended with 450 ml solubilization buffer containing 
20 mM Tris-citrate (pH 7.4), 1% Triton X-100 (membrane 
biochemistry grade, Boehringer Mannheim), 1 mM NaaDTA, 
0.5 mM dithiothreitol and 100 mg/l bacitracin. The mixture 
was stirred for 30 min on ice and sedimented at 48000 x g for 
3 h to remove detergent-insoluble membrane components. 
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2.2. 1012-S affinity chromatography 
The affinity column of 1012~S-acetamide adipic hydrazide 
bound to Sepharose 4B was synthesized following the procedure 
of Taguchi and Kuriyama [24] using 1012-S graciously provided 
by Dr Kentaro Hirai (Shionogi Research Laboratories, Osaka). 
A 25 ml bed volume gel was prepared from 7.5 g CNBr- 
activated Sepharose 4B and 40 mg 1012-S. A similar column 
was also prepared substituting 60 mg glutamate for 1012-S. 
The columns were equilibrated at 4°C with buffer consisting 
of 50 mM Tris-citrate (pH 7.2) with 0.1 mM NazEDTA and 
0.1% Triton X-100. The 400-ml samples of solubilized receptor 
were passed in series over the glutamate column followed by the 
1012-S column at a rate of 12 ml/h. More than 90% of the 
benzodiazepine-binding sites passed through the glutamate col- 
umn. The high affinity of 1012-S for the benzodiazepine- 
binding site precluded assay of this site with radioligand follow- 
ing specific elution with 1012-S. To permit assay of the 
benzodiazepine-binding site through subsequent anion- 
exchange chromatography, GABAI\ receptor was eluted from 
the 1012-S affinity column with 140 ml of 1 M NaSCN in 
equilibration buffer, rather than with 1012-S. These affinity 
column eluates were dialyzed vs three changes, 4 l/change, of 
20 mM T&-citrate @H 7.2), containing 0.04 NazEDTA and 
0.04% Triton X-100 (dialysis buffer) to reduce the NaSCN con- 
centration. 
2.3. Anion-exchange HPLC 
Following dialysis, affinity-purified receptor was concen- 
trated from 100 to 30 ml using a NovacelVFiltron membrane of 
100 kDa cutoff. This concentrated sample, or in some cases 
10 ml solubilized membrane protein, was applied in 2-ml ali- 
quots at a rate of 1 ml/min to a Mono-Q DEAE ion-exchange 
column (Pharmacia, 0.5 x 25 cm) using a Gilson gradient 
HPLC system. The column was washed with 20 ml of 50 mM 
Tris-citrate (PH 7.2) with 10% sucrose and 0.1 mM NazEDTA. 
The receptor was retained by the column under these conditions 
and eluted with a 60 ml linear gradient of O-l .2 M KC1 in the 
same buffer at a rate of 1 ml/min. Aliquots of alternate l-ml 
fractions were assayed directly for [‘H]flunitrazepam or 
[‘Hlmuscimol binding. Fractions containing GABAA receptors 
were pooled as either early (0.3-0.6 M KCI) or late (0.7-LO M 
KCl) eluting peaks of ligand-binding activity. These were 
dialyzed against dialysis buffer and either reapplied to the 
anion-exchange column or assayed for ligand-binding prop- 
erties. 
2.4. Ligand-binding assays 
Receptor fractions were incubated in polypropylene tubes on 
ice for 45 min with either 8-10 nM [‘H]flunitrazepam (spec. 
act. 79-90 Ci/mmol, NEN) or 20 nM [3H]muscimol (spec. act. 
6-20 Ci/mmol, NEN) in 50 mM Tris-citrate (pH 7.2). Incuba- 
tions were conducted with and without 100 M unlabeled 
flunitrazepam or 1 mM GABA. Samples were filtered through 
polyethylenimine-treated glass-fiber (Whatman GF/B) filters as 
described by Bruns et al. [25] for trapping of detergent- 
solubilized proteins. For estimates of receptor-ligand affinity, 
assays were performed in triplicate with 8 concentrations of 
[3H]flunitrazepam between 0.5 and 100 nM or 7 concentrations 
of [‘Hlmuscimol between 3 and 200 nM. Specific binding was 
estimated as the difference between assays in the presence and 
absence of excess unlabeled flunitrazepam or GABA. 
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For competition assays, 7 concentrations of unlabeled CL 
218872 from 10 nM to 10pM were included in equilibrium 
binding assays as described above in which the concentration of 
[3H]flunitrazepam was either 2 or 4 nM. 
Protein values for Triton X-lOO-solubilized samples were ob- 
tained using the bicinchoninic acid method [26] with commer- 
cial reagents (Pierce) and bovine serum albumin as standard. 
Radioligand-binding data were analyzed using EBDA and 
LIGAND computer programs, as adapted for the IBM PC by 
McPherson [27]. The EBDA program provided initial estimates 
of binding parameters for different binding isotherm models, 
while the LIGAND programs’ non-linear curve-fitting 
subroutines were used to identify the curves which most closely 
approximated the data. 
3. RESULTS 
The profile of [3H]flunitrazepam binding which 
eluted from the anion-exchange HPLC column 
with increasing salt concentration is presented in 
fig.1. The larger peak of binding sites typically 
eluted with 0.3-0.6 M KCl, while a smaller peak 
eluted later with 0.7-1.0 M KCI. The relative 
quantity of benzodiazepine binding in these peaks 
varied between preparations with the later eluting 
fraction always containing fewer binding sites. In 
seven HPLC analyses of affinity-purified receptor, 
the average ratio of [3H]flunitrazepam in peak 1 vs 
peak 2 was 2.4: 1 (2.4 + 0.6 SD). The distribution 
of [3H]muscimol-binding sites mirrored that 
observed for [3H]flunitrazepam binding (fig.2) in 
the KC1 eluate from this column. 
When the receptor which eluted between 0.3 and 
0.6 M KC1 was collected, dialyzed and 
rechromatographed under the same HPLC condi- 
tions, the ligand binding remained as a single peak, 
retaining the original elution characteristics with 
respect to the salt concentration (fig.3). Similarly, 
the collection, dialysis and rechromatography of 
the later eluting GABAn receptor produced a single 
large peak which eluted with the higher salt con- 
centration, and a much smaller peak corre- 
sponding to the early eluting form (fig.4). 
The two ionic peaks obtained from anion- 
exchange chromatography were assayed for both 
[3H]flunitrazepam and [3H]muscimol binding and 
the receptor/ligand affinity data obtained from 
each were similar. Estimated single-site Kd values 
were 3.0-5.0 nM for benzodiazepine binding and 
7.0-7.3 nM for muscimol binding. The binding 
isotherms for the affinity column and HPLC 
eluates could also be resolved by the LIGAND pro- 
gram into two affinity states for both the 
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Fig. 1. [3H]Flunitrazepam binding to GABAA receptors resolved 
on anion-exchange HPLC is presented. The receptors, 
solubilized from Pl membranes, were purified on a 1012-S 
affinity column, eluted with NaSCN, applied to HPLC in 
50 mM Tris-citrate (pH 7.4) containing 10% sucrose and 0.1% 
Triton. The column was washed with the same buffer for 
20 min and eluted with a gradient of KC1 from 0 to 1.2 M over 
60 min. The flow rate throughout he procedure was 1 ml/min. 
Aliquots (0.2 ml) of alternate l-ml fractions were assayed for 
benzodiazepine binding using 10 nM [3H]flunitrazepam. 
Similar elution profiles were obtained from 7 experiments. 
benzodiazepine-binding (Kd ranges 0.2-l .6 and 
52-88 nM) and muscimol-binding site (Kd ranges 
1.6-2.4 and 32-68 nM). The receptors solubilized 
with detergent from Pl membranes exhibited 
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Fig.2. [‘HlFlunitrazepam (o---o) and [‘Hlmuscimol (c+-+) 
binding to GABAA receptors resolved on anion-exchange 
HPLC is presented. The receptor, solubilized from P2 
membranes, purified on a 1012-S affinity column, eluted with 
NaSCN and chromatographed on DEAE anion-exchange 
HPLC, as described in fig.1. Aliquots (0.5 ml) of alternate l-ml 
fractions were assayed with 10 nM [‘Hlflunitrazepam and 
20 nM [‘H]muscimol. Similar results were obtained from two 
experiments. 
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Fig.3. [‘H]Flunitrazepam binding to the early eluting GABAA 
receptor population which eluted with 0.3-0.6 M KC1 on an 
initial DEAF, anion-exchange HPLC column (inset), was 
dialyzed, concentrated and rechromatographed under the same 
conditions. Chromatography was as described in fig. 1. Aliquots 
(0.25 ml) of alternate l-ml fractions were assayed from the first 
elution and the entire 1 ml fraction was assayed from the 
second elution. Similar data were obtained in two analyses of 
the early eluting population of GABA* receptors. 
single affinity binding sites for [3H]flunitrazepam 
of 6.1 nM (Hill coefficient, 1 .O) and for 
[3H]muscimol of 18 nM (Hill coefficient, 1.02). 
In order to assess the possibility that the two 
peaks of binding activity identified by anion ex- 
change represented type I and II receptors, the sen- 
sitivity of their [‘H]flunitrazepam binding to 
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Fig.4. [3H]Flunitrazepam binding to late eluting GABAA 
receptor population which eluted with 0.7-1.0 M KC1 on an 
initial DEAB anion-exchange HPLC column (inset), was 
dialyzed, concentrated and rechromatographed under the same 
conditions. Chromatography was as described in fig. 1. Aliquots 
(0.2 ml) of alternate l-ml fractions were assayed from the first 
elution and O&ml aliquots of l-ml fractions from the second 
elution were assayed. 
displacement with CL 218872 was assayed. The CL 
218872-binding affinity was estimated from 
Hofstee [28] transformations of the data. The first 
HPLC peak exhibited CL 218872 affinities of 
36 nM and 1.8 pM (at 2 nM [3H]flunitrazepam) 
and 47 nM and 2 pM (at 4 nM [3H]flunitrazepam), 
while the later eluting receptor exhibited affinities 
of 47 nM/2.7 PM and 73 nM/3 pM. Analysis of 
these data in Hofstee transformation plots (070 
radioligand displaced vs 070 displaced/CL 218872 
concentration) produced very similar curves for 
the two ionic peaks, a result which suggests that 
the proportion of the CL 218872-defined type I 
and II receptors in the two peaks is similar. 
4. DISCUSSION 
Two populations of GABAA receptor have been 
resolved by anion-exchange HPLC. Differential 
elution of these populations with a salt gradient 
suggests that they possess differing densities of 
anionic groups by which they interact with the 
high-performance column. Despite this apparent 
chemical difference, these populations appear to 
be similar in terms of their affinity for 
flunitrazepam, muscimol and CL 218872. 
Differences which have been reported between 
presumptive subclasses of GABAA receptors in- 
clude differential solubility in detergent [ 13,141, 
multiple [3H]flumtrazepam-photolabeled receptor 
subunits [16], and differential sensitivity to 
glycosidase treatment [19,21]. Additionally, 
subclasses of GABAA receptors possess differing 
affinities for CL 218872 and ,&carbolines [7-121. 
Consistent with studies on other neurotransmitter 
receptors, these data suggest that there may be 
considerable structural diversity in the GABAA 
receptor. 
It is possible that these ionic populations have 
been produced as a consequence of the affinity 
chromatography or concentration of the sample 
prior to HPLC. To address this possibility, a 
Triton-solubilized brain membrane preparation 
was chromatographed on HPLC without any 
purification step or sample concentration. Due to 
the greatly increased protein concentration in this 
sample, the peaks of benzodiazepine binding were 
slightly less well articulated, however, both were 
clearly resolved at the appropriate point in the KC1 
elution gradient. The failure of the early and late 
84 
Volume 247, number 1 FEBS LETTERS April 1989 
eluting receptor isolates to exhibit interconversion 
between sequential HPLC analyses militates 
against the view that they are in a dynamic 
equilibrium in vitro. Additionally, while there was 
variation in the relative amounts of binding activi- 
ty in the ionic peaks between preparations, we 
detected no correlation between this variation and 
the time in vitro before HPLC. 
Transmitter receptor and ion channel 
heterogeneity is emerging as a consistent heme in 
neurobiology. Variation in subunit composition, 
glycosylation and phosphorylation may each con- 
tribute to this diversity and may reflect differences 
in cellular localization, functional state or 
metabolic condition of the receptor complex. If the 
differences described here in GABAA receptor 
mobility during ion-exchange chromatography are 
physiologically relevant, this HPLC-based resolu- 
tion of receptor subtype will be useful in obtaining 
structure/function correlates, which complement 
subunit cDNA sequence information. 
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